Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Stopped Quality of the data originating from prior versions of the protocol has been affected by protocol deviations triggered by the COVID-19 pandemics

Conditions

• Breast Cancer
• HER2-positive Breast Cancer
• HER-2 Gene Amplification
• HER2 Positive Breast Carcinoma
• HER-2 Protein Overexpression
• Breast Cancer, Male
• Breast Cancer Female

Interventions

• BIOLOGICAL: HER2 DC1 Vaccine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute